4.20
0.08 (1.94%)
Penutupan Terdahulu | 4.12 |
Buka | 4.31 |
Jumlah Dagangan | 57,456 |
Purata Dagangan (3B) | 138,945 |
Modal Pasaran | 1,491,449,344 |
Harga / Pendapatan (P/E Ke hadapan) | 59.88 |
Harga / Jualan (P/S) | 1.43 |
Harga / Buku (P/B) | 1.31 |
Julat 52 Minggu | |
Tarikh Pendapatan | 13 Aug 2025 |
Margin Keuntungan | -26.26% |
Margin Operasi (TTM) | -9.91% |
EPS Cair (TTM) | -0.690 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 52.48% |
Nisbah Semasa (MRQ) | 2.03 |
Aliran Tunai Operasi (OCF TTM) | 34.59 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.11 M |
Pulangan Atas Aset (ROA TTM) | -2.42% |
Pulangan Atas Ekuiti (ROE TTM) | -20.51% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
Stok | Evotec SE | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -2.5 |
Purata | 0.38 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
Sektor | Healthcare |
Industri | Drug Manufacturers - Specialty & Generic |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Institusi | 2.56% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Dcf Advisers, Llc | 31 Mar 2025 | 751,579 |
Abc Arbitrage Sa | 31 Mar 2025 | 77,919 |
Fore Capital, Llc | 31 Mar 2025 | 17,005 |
Quadrant Capital Group Llc | 31 Mar 2025 | 5,300 |
Julat 52 Minggu | ||
Median | 7.00 (66.67%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 14 Aug 2025 | 7.00 (66.67%) | Beli | 3.82 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
13 Aug 2025 | Pengumuman | Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution |
06 Aug 2025 | Pengumuman | Evotec SE to announce first half-year results 2025 on 13 August 2025 |
30 Jul 2025 | Pengumuman | Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site |
30 Jul 2025 | Pengumuman | Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site |
21 Jul 2025 | Pengumuman | Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix |
21 Jul 2025 | Pengumuman | Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance |
25 Jun 2025 | Pengumuman | Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |